Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab.

Bruckert E, Kereiakes DJ, Koren MJ, Louie MJ, Letierce A, Miller K, Cannon CP.

J Clin Lipidol. 2019 May - Jun;13(3):443-454. doi: 10.1016/j.jacl.2019.04.005. Epub 2019 Apr 10.

2.

Does prior dengue virus exposure worsen clinical outcomes of Zika virus infection? A systematic review, pooled analysis and lessons learned.

Masel J, McCracken MK, Gleeson T, Morrison B, Rutherford G, Imrie A, Jarman RG, Koren M, Pollett S.

PLoS Negl Trop Dis. 2019 Jan 25;13(1):e0007060. doi: 10.1371/journal.pntd.0007060. eCollection 2019 Jan.

3.

Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies.

Stroes E, Robinson JG, Raal FJ, Dufour R, Sullivan D, Kassahun H, Ma Y, Wasserman SM, Koren MJ.

Clin Cardiol. 2018 Oct;41(10):1328-1335. doi: 10.1002/clc.23049. Epub 2018 Oct 21.

4.

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina.

Depre C, Antalik L, Starling A, Koren M, Eisele O, Lenz RA, Mikol DD.

Headache. 2018 May;58(5):715-723. doi: 10.1111/head.13316.

5.

Physicians' Views on Advance Care Planning and End-of-Life Care Conversations.

Fulmer T, Escobedo M, Berman A, Koren MJ, Hernández S, Hult A.

J Am Geriatr Soc. 2018 Jul;66(6):1201-1205. doi: 10.1111/jgs.15374. Epub 2018 May 23.

PMID:
29797314
6.

Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications.

Wasserman SM, Sabatine MS, Koren MJ, Giugliano RP, Legg JC, Emery MG, Doshi S, Liu T, Somaratne R, Gibbs JP.

J Cardiovasc Pharmacol Ther. 2018 Sep;23(5):423-432. doi: 10.1177/1074248418774043. Epub 2018 May 16.

PMID:
29768954
7.

Abnormalities in the relationship of paraoxonase 1 with HDL and apolipoprotein A1 and their possible connection to HDL dysfunctionality in type 2 diabetes.

Viktorinova A, Jurkovicova I, Fabryova L, Kinova S, Koren M, Stecova A, Svitekova K.

Diabetes Res Clin Pract. 2018 Jun;140:174-182. doi: 10.1016/j.diabres.2018.03.055. Epub 2018 Apr 5.

PMID:
29626583
8.

Simultaneous Immunodetection of Anthrax, Plague, and Tularemia from Blood Cultures by Use of Multiplexed Suspension Arrays.

Mechaly A, Vitner E, Levy H, Weiss S, Bar-David E, Gur D, Koren M, Cohen H, Cohen O, Mamroud E, Fisher M.

J Clin Microbiol. 2018 Mar 26;56(4). pii: e01479-17. doi: 10.1128/JCM.01479-17. Print 2018 Apr.

9.

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.

Modjarrad K, Lin L, George SL, Stephenson KE, Eckels KH, De La Barrera RA, Jarman RG, Sondergaard E, Tennant J, Ansel JL, Mills K, Koren M, Robb ML, Barrett J, Thompson J, Kosel AE, Dawson P, Hale A, Tan CS, Walsh SR, Meyer KE, Brien J, Crowell TA, Blazevic A, Mosby K, Larocca RA, Abbink P, Boyd M, Bricault CA, Seaman MS, Basil A, Walsh M, Tonwe V, Hoft DF, Thomas SJ, Barouch DH, Michael NL.

Lancet. 2018 Feb 10;391(10120):563-571. doi: 10.1016/S0140-6736(17)33106-9. Epub 2017 Dec 5.

10.

Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus.

Sattar N, Toth PP, Blom DJ, Koren MJ, Soran H, Uhart M, Elliott M, Cyrille M, Somaratne R, Preiss D.

Am J Cardiol. 2017 Nov 1;120(9):1521-1527. doi: 10.1016/j.amjcard.2017.07.047. Epub 2017 Jul 31.

PMID:
28844508
11.

PCSK9 Inhibitors, Statins, Low-Density Lipoprotein Cholesterol, Mevalonate Pathway, and Toxicity-Reply.

Koren MJ, Sabatine MS.

JAMA Cardiol. 2017 Oct 1;2(10):1169. doi: 10.1001/jamacardio.2017.2734. No abstract available.

PMID:
28813546
12.

Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.

Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, Ruzza A, Ma Y, Somaratne R, Raal FJ.

JAMA Cardiol. 2017 Jun 1;2(6):598-607. doi: 10.1001/jamacardio.2017.0747.

13.

Management of Relocation in Cognitively Intact Older Adults.

Hertz JE, Koren ME, Rossetti J, Tibbits K.

J Gerontol Nurs. 2016 Nov 1;42(11):14-23. doi: 10.3928/00989134-20160901-05. Epub 2016 Sep 6.

PMID:
27598268
14.

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients.

Stein E, Bays H, Koren M, Bakker-Arkema R, Bisgaier C.

J Clin Lipidol. 2016 Sep-Oct;10(5):1212-22. doi: 10.1016/j.jacl.2016.08.002. Epub 2016 Aug 10.

15.

Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome.

Blom DJ, Koren MJ, Roth E, Monsalvo ML, Djedjos CS, Nelson P, Elliott M, Wasserman SM, Ballantyne CM, Holman RR.

Diabetes Obes Metab. 2017 Jan;19(1):98-107. doi: 10.1111/dom.12788. Epub 2016 Oct 14.

PMID:
27619750
16.

Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice.

Sabatine MS, Underberg JA, Koren M, Baum SJ.

Postgrad Med. 2016 Oct;128 Suppl 1:31-9. doi: 10.1080/00325481.2016.1208895. Epub 2016 Jul 14.

PMID:
27422124
17.

[Management of treatment in patients with neuroendocrine neoplasmas of digestive tract].

Kinová S, Kovácová M, Caprnda M, Koren M.

Vnitr Lek. 2015 Dec;61(12 Suppl 5):5S12-20. Slovak.

PMID:
27124967
18.

Genital herpes.

Koren M, Decker CF.

Dis Mon. 2016 Aug;62(8):287-93. doi: 10.1016/j.disamonth.2016.03.013. Epub 2016 Apr 22. Review. No abstract available.

PMID:
27109044
19.

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.

Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Blom D, Seidah NG, Honarpour N, Lira A, Xue A, Chiruvolu P, Jackson S, Di M, Peach M, Somaratne R, Wasserman SM, Scott R, Stein EA.

J Lipid Res. 2016 Jun;57(6):1086-96. doi: 10.1194/jlr.P065334. Epub 2016 Apr 21.

20.

Type-specific clinical characteristics of adenovirus-associated influenza-like illness at five US military medical centers, 2009-2014.

Koren MA, Arnold JC, Fairchok MP, Lalani T, Danaher PJ, Schofield CM, Rajnik M, Hansen EA, Mor D, Chen WJ, Ridoré M, Burgess TH, Millar EV.

Influenza Other Respir Viruses. 2016 Sep;10(5):414-20. doi: 10.1111/irv.12392. Epub 2016 May 13.

21.

The epidemiology of herpes simplex virus type 2 infections in a large cohort of HIV-infected patients, 2006-2014.

Koren M, Wang X, Blaylock JM, Okulicz JF, Whitman TJ, Deiss RG, Ferguson TM, O'Bryan TA, Sanchez JL, Lalani T, Agan BK, Macalino GE, Ganesan A.

MSMR. 2016 Mar;23(3):11-5. No abstract available.

PMID:
27030927
22.

Report on milestones for care and support under the U.S. National Plan to Address Alzheimer's Disease.

Alzheimer's Association National Plan Care and Support Milestone Workgroup, Borson S, Boustani MA, Buckwalter KC, Burgio LD, Chodosh J, Fortinsky RH, Gifford DR, Gwyther LP, Koren MJ, Lynn J, Phillips C, Roherty M, Ronch J, Stahl C, Rodgers L, Kim H, Baumgart M, Geiger A.

Alzheimers Dement. 2016 Mar;12(3):334-69. doi: 10.1016/j.jalz.2016.01.005. Epub 2016 Feb 8.

23.

[Management of treatment in patients with neuroendocrine neoplasmas of digestive tract].

Kiňová S, Kováčová M, Čaprnda M, Koreň M.

Vnitr Lek. 2015;61 Suppl 5:12-20. Czech.

PMID:
26800468
24.

Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy.

Koren MJ, Kereiakes D, Pourfarzib R, Winegar D, Banerjee P, Hamon S, Hanotin C, McKenney JM.

J Am Heart Assoc. 2015 Nov 19;4(11). pii: e002224. doi: 10.1161/JAHA.115.002224.

25.

Insights Into Statin Intolerance.

Kopecky S, Baum S, Foody JM, Koren M, McKenney J, Sperling L, Wong ND; Statin Intolerance Roundtable Participants.

Clin Cardiol. 2015 Sep;38(9):520-6. doi: 10.1002/clc.22432. Epub 2015 Sep 3. No abstract available.

26.

War wound treatment complications due to transfer of an IncN plasmid harboring bla(OXA-181) from Morganella morganii to CTX-M-27-producing sequence type 131 Escherichia coli.

McGann P, Snesrud E, Ong AC, Appalla L, Koren M, Kwak YI, Waterman PE, Lesho EP.

Antimicrob Agents Chemother. 2015;59(6):3556-62. doi: 10.1128/AAC.04442-14. Epub 2015 Apr 13.

27.

The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials.

Preiss D, Campbell RT, Murray HM, Ford I, Packard CJ, Sattar N, Rahimi K, Colhoun HM, Waters DD, LaRosa JC, Amarenco P, Pedersen TR, Tikkanen MJ, Koren MJ, Poulter NR, Sever PS, Ridker PM, MacFadyen JG, Solomon SD, Davis BR, Simpson LM, Nakamura H, Mizuno K, Marfisi RM, Marchioli R, Tognoni G, Athyros VG, Ray KK, Gotto AM, Clearfield MB, Downs JR, McMurray JJ.

Eur Heart J. 2015 Jun 21;36(24):1536-46. doi: 10.1093/eurheartj/ehv072. Epub 2015 Mar 23. Review.

28.

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators.

N Engl J Med. 2015 Apr 16;372(16):1500-9. doi: 10.1056/NEJMoa1500858. Epub 2015 Mar 15.

29.

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ; ODYSSEY LONG TERM Investigators.

N Engl J Med. 2015 Apr 16;372(16):1489-99. doi: 10.1056/NEJMoa1501031. Epub 2015 Mar 15.

30.

[Clinical and microbiological characteristics of severe infections caused by group A streptococci].

Hupková H, Zaborská M, Sisovský V, Babál P, Simaljaková M, Koren M, Reis R, Kozáková J.

Epidemiol Mikrobiol Imunol. 2014 Sep;63(3):164-7. Czech.

PMID:
25642472
31.

Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis.

Koren MJ, Roth EM, McKenney JM, Gipe D, Hanotin C, Ferrand AC, Wu R, Dufour R.

Postgrad Med. 2015 Mar;127(2):125-32. doi: 10.1080/00325481.2015.998987. Epub 2015 Jan 22.

PMID:
25609019
32.

FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity.

Lehrer-Graiwer J, Singh P, Abdelbaky A, Vucic E, Korsgren M, Baruch A, Fredrickson J, van Bruggen N, Tang MT, Frendeus B, Rudd JHF, Hsieh F, Ballantyne CM, Ghoshhajra B, Rosenson RS, Koren M, Roth EM, Duprez DA, Fayad ZA, Tawakol AA.

JACC Cardiovasc Imaging. 2015 Apr;8(4):493-494. doi: 10.1016/j.jcmg.2014.06.021. Epub 2014 Nov 12. No abstract available.

33.

Interventional studies to support the spiritual self-care of health care practitioners: an integrative review of the literature.

Koren ME, Purohit S.

Holist Nurs Pract. 2014 Sep-Oct;28(5):291-300. doi: 10.1097/HNP.0000000000000044. Review.

PMID:
25099982
34.

Characterization of infections with extended-spectrum β-lactamase producing Escherichia coli and Klebsiella species at a major military medical center.

Koren M, Demons S, Murray C, Mahlen S, Schofield C.

Mil Med. 2014 Jul;179(7):787-92. doi: 10.7205/MILMED-D-13-00473.

PMID:
25003866
35.

[Catheter related septic central venous thrombosis of the superior vena cava and right atrium: case reports-editorial].

Murin J, Koreň M, Papinčak J, Kiňová S.

Vnitr Lek. 2014 Feb;60(2):106-7. Czech. No abstract available.

PMID:
24851318
36.

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.

Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, Kim JB, Scott R, Wasserman SM, Bays H; MENDEL-2 Investigators.

J Am Coll Cardiol. 2014 Jun 17;63(23):2531-2540. doi: 10.1016/j.jacc.2014.03.018. Epub 2014 Mar 29.

37.

Is the hospital's magnet status linked to HCAHPS scores?

Chen J, Koren ME, Munroe DJ, Yao P.

J Nurs Care Qual. 2014 Oct-Dec;29(4):327-35. doi: 10.1097/NCQ.0000000000000062.

PMID:
24686041
38.

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Stein EA; DESCARTES Investigators.

N Engl J Med. 2014 May 8;370(19):1809-19. doi: 10.1056/NEJMoa1316222. Epub 2014 Mar 29.

39.

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.

Stein EA, Giugliano RP, Koren MJ, Raal FJ, Roth EM, Weiss R, Sullivan D, Wasserman SM, Somaratne R, Kim JB, Yang J, Liu T, Albizem M, Scott R, Sabatine MS; PROFICIO Investigators.

Eur Heart J. 2014 Sep 1;35(33):2249-59. doi: 10.1093/eurheartj/ehu085. Epub 2014 Mar 4.

PMID:
24598985
40.

Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent R, Wasserman SM, Huang F, Xue A, Albizem M, Scott R, Stein EA.

J Am Coll Cardiol. 2014 Apr 8;63(13):1278-1288. doi: 10.1016/j.jacc.2014.01.006. Epub 2014 Feb 5.

41.

Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.

Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, Civeira F, Somaratne R, Nelson P, Liu T, Scott R, Wasserman SM, Sabatine MS; OSLER Investigators.

Circulation. 2014 Jan 14;129(2):234-43. doi: 10.1161/CIRCULATIONAHA.113.007012. Epub 2013 Nov 19.

PMID:
24255061
42.

Weight-loss maintenance among SHIFT pilot study participants 30-months after intervention.

Wipfli B, Olson R, Koren M.

J Occup Environ Med. 2013 Jan;55(1):1-3. doi: 10.1097/JOM.0b013e31827db848. No abstract available.

43.

Spirituality of staff nurses: application of modeling and role modeling theory.

Koren ME, Papadimitriou C.

Holist Nurs Pract. 2013 Jan-Feb;27(1):37-44. doi: 10.1097/HNP.0b013e318276fc38. Erratum in: Holist Nurs Pract. 2013 May-Jun;27(3):184. Papamiditriou, Christina [corrected to Papadimitriou, Christina].

PMID:
23211387
44.

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study.

Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, Bolognese M, Wasserman SM.

Lancet. 2012 Dec 8;380(9858):1995-2006. doi: 10.1016/S0140-6736(12)61771-1. Epub 2012 Nov 6.

PMID:
23141812
45.

The preferences for everyday living inventory: scale development and description of psychosocial preferences responses in community-dwelling elders.

Van Haitsma K, Curyto K, Spector A, Towsley G, Kleban M, Carpenter B, Ruckdeschel K, Feldman PH, Koren MJ.

Gerontologist. 2013 Aug;53(4):582-95. doi: 10.1093/geront/gns102. Epub 2012 Aug 30.

PMID:
22936532
46.

Creating a culture of evidence in nursing education using student portfolios.

Rossetti J, Oldenburg N, Fisher Robertson J, Coyer SM, Koren ME, Peters B, Uhlken C, Musker K.

Int J Nurs Educ Scholarsh. 2012 Jun 9;9. pii: /j/ijnes.2012.9.issue-1/1548-923X.2415/1548-923X.2415.xml. doi: 10.1515/1548-923X.2415.

PMID:
22706264
47.

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA.

J Am Coll Cardiol. 2012 Jun 19;59(25):2344-53. doi: 10.1016/j.jacc.2012.03.007. Epub 2012 Mar 28.

48.

Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia.

Koren MJ, Hamad A, Klasen S, Abeyratne A, McNutt BE, Kalra S.

Am J Health Syst Pharm. 2011 May 1;68(9):818-27. doi: 10.2146/ajhp100260. Erratum in: Am J Health Syst Pharm. 2011 Aug 1;68(15):1374.

PMID:
21515866
49.

Reducing perceived barriers to nursing homes data entry in the advancing excellence campaign: the role of LANEs (Local Area Networks for Excellence).

Bakerjian D, Bonner A, Benner C, Caswell C, Weintraub A, Koren MJ.

J Am Med Dir Assoc. 2011 Sep;12(7):508-17. doi: 10.1016/j.jamda.2010.03.014. Epub 2010 Oct 2.

PMID:
21450175
50.

[Gastroenteropatic neuroendocrine tumors: multidisciplinary approach in therapy].

Kinová S, Kekenák L, Kovácová E, Koren M.

Vnitr Lek. 2010 Sep;56(9 Suppl):946-50. Slovak.

PMID:
21137165

Supplemental Content

Support Center